Healthcare Industry News: orally disintegrating tablet
News Release - December 4, 2006
Cephalon, Inc. Appoints Dr. Raj Khankari as General Manager of CIMA LABSFRAZER, Pa., Dec. 4 (HSMN NewsFeed) -- Cephalon, Inc. (Nasdaq: CEPH ) today announced the appointment of Raj Khankari, Ph.D. as General Manager of CIMA LABS, its wholly owned drug delivery subsidiary, effective immediately.
In his new position, Khankari is responsible for CIMA LABS and for the growth of Cephalon's drug delivery business. He will maintain his current responsibilities as Vice President of Worldwide Drug Delivery Technology reporting to Peter Grebow Ph.D., Executive Vice President of Worldwide Technical Operations.
"Raj's experience over his 12-year tenure makes him uniquely qualified to lead our drug delivery business," said Grebow. "He has been instrumental in the development and successful launch of several prescription and over-the- counter products for CIMA LABS, and has identified and developed strong synergies among Cephalon drug delivery sites."
Khankari contributed to the development and launch of partner products such as Wyeth's Alavert®, AstraZeneca's Zomig® ZMT, Organon's Remeron Soltabs® Novartis' Triaminic® Softchews, and the newest Cephalon product, FENTORA(TM) (fentanyl buccal tablet) [C-II], for cancer patients with breakthrough pain.
CIMA LABS INC. is a leading drug delivery technology company that develops and manufactures prescription and over-the-counter pharmaceutical products based on proprietary, orally disintegrating technologies. CIMA LABS' seven prescription and three over-the-counter products are distributed globally by its pharmaceutical partners and are based on OraSolv® and DuraSolv® orally disintegrating tablet (ODT) technologies. The tablets disintegrate quickly in the mouth without chewing or the need for water - making it easier for patients to take medication. CIMA LABS also developed OraVescent®, an oral transmucosal technology. The first product candidate using OraVescent technology is in Phase III clinical trials.
CIMA LABS, located in suburban Minneapolis, is a wholly owned subsidiary of Cephalon, Inc. and serves as one of Cephalon's U.S. manufacturing sites. Further information may be obtained at http://www.cimalabs.com.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pa., and offices, laboratories or manufacturing facilities in West Chester, Pa.; Salt Lake City, and suburban Minneapolis. Cephalon's European headquarters are located in Maisons-Alfort, France.
The company currently markets six proprietary products in the United States: PROVIGIL® (modafinil) Tablets [C-IV], FENTORA(TM) (fentanyl buccal tablet) [C-II], ACTIQ® (oral transmucosal fentanyl citrate) [C-II], GABITRIL® (tiagabine hydrochloride), TRISENOX® (arsenic trioxide) injection, and VIVITROL® (naltrexone for extended-release injectable suspension). Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products, including the prospects for and timing of regulatory approval of NUVIGIL; intellectual property protection for its products, including the new composition of matter patent for NUVIGIL, the likelihood that polymorphic Form I compositions of matter will be found in other formulations of armodafinil that may be developed and the breadth and strength of this NUVIGIL patent until its expiration date; interpretation of clinical results; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.